ARMP 2.36 Armata Pharmaceuticals, Inc.
| Range: | 1.9-4.48 | Vol Avg: | 7370 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.81 | Cap: | 0.09B | Currency: | USD | Exchange: | AMEX |
| Sector: | Healthcare | IPO: | Fri May 20 1994 | Empoloyees: | 66 | ||
| CUSIP: | 04216R102 | CIK: | 0000921114 | ISIN: | US04216R1023 | Country: | US |
| CEO: | Dr. Deborah L. Birx M.D. | Website: | https://www.armatapharma.com | ||||
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow